Prostate-specific oncolytic adenovirus CG7870 and Docetaxel combination

CG7870 (also known as CV787) is a prostate-specific, replication-competent oncolytic adenovirus designed to selectively target and lyse prostate cancer cells (DeWeese et al., 2001, Cancer Res). Its replication is transcriptionally regulated by the prostate-specific antigen (PSA) and human kallikrein 2 (hK2) promoters, which restricts viral activity to cells expressing these prostate-specific markers (Small et al., 2006, J Clin Oncol). Docetaxel is a taxane-based chemotherapy agent that functions as a microtubule stabilizer, binding to beta-tubulin to inhibit mitotic spindle assembly and induce cell cycle arrest (PubChem, CID 148424). The combination of CG7870 and docetaxel is designed to achieve synergistic anti-tumor activity by combining the direct cytolytic effects of the virus with the cytotoxic effects of the microtubule-targeting drug. This therapeutic strategy has been primarily explored in clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinical studies suggested that docetaxel could enhance the replication and cell-killing ability of the oncolytic virus, while the virus could sensitize cells to chemotherapy. Despite promising early-phase results, the development of this specific combination has faced challenges common to systemic oncolytic virus delivery, including neutralizing antibodies and sequestration in the liver.

Other names

CV787CG7870DocetaxelTaxotereOncolytic adenovirus and microtubule stabilizer combination

CG7870 is an oncolytic adenovirus that replicates selectively in prostate cells via PSA and hK2 promoters, causing cell lysis (DeWeese et al., 2001). Docetaxel stabilizes microtubules by binding to beta-tubulin, leading to mitotic arrest and apoptosis (PubChem, CID 148424). The combination provides synergistic cytotoxicity by combining viral-mediated oncolysis with microtubule-targeted chemotherapy.